Modifying a Registro Sanitario in Colombia: Legal vs Technical Changes

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Colombia has made changes to a registration certificate explicitly procedural through Decreto 582 de 2017 and explicitly priced through Resolución 2025067543, dividing them into two channels: changes of a legal nature and changes of a technical nature. A legal-nature change costs COP 826,546; a technical-nature change costs COP 1,060,243 — a difference of roughly COP 233,697.

The classification path is equally clear: if the change falls within the list of legal documents in Decreto 4725 de 2005, Art. 19, it follows the legal-nature channel; if it falls within the list of technical documents in Art. 18, it follows the technical-nature channel. GRZAN’s judgment is that the real expense is not the fee gap but the rejection and lost time caused by classifying wrongly — filing a technical-nature change under the legal-nature channel leads directly to rejection of the application and burns the 90-day deficiency response period (a practical estimate) for nothing.

2. Legal basis

RegulationNumberPublication dateProvisions
Decreto 4725 de 2005 (registration, marketing authorization and health surveillance regime for medical devices)DECRETO 4725 DE 26 DE DICIEMBRE DE 2005December 26, 2005Art. 18 (technical document list), Art. 19 (legal document list), Art. 20 (certificate contents), Art. 29 (POA)
Decreto 582 de 2017 (amending Decreto 4725 de 2005)Decreto 0582 de 2017April 4, 2017Change procedure provisions
Resolución 2025067543 (2026 fee schedule)Resolución 2025067543December 22, 2025Fee schedule: legal-nature change COP 826,546; technical-nature change COP 1,060,243
Resolución 2026033499 (partial amendment of the fee schedule)Resolución 2026033499June 30, 2026Provisions partially amending Resolución 2025067543
Resolución 4002 de 2007 (storage and repackaging capability manual)Resolución 4002 de 20072007CCAA valid 5 years; re-inspection must be requested at least 5 business days before expiry
Ley 1437 de 2011 (CPACA, administrative procedure code)Ley 1437 de 20112011Administrative procedure provisions governing deficiency responses and cancellation

3. Expert insights

1. Classification looks at which list is touched, not at which words were changed

Companies often ask whether replacing a manufacturer’s name counts as a technical change. GRZAN’s method is to first identify which document the change affects, then determine whether that document belongs to Art. 18 or Art. 19. The titular name and address (Art. 20), the POA (Art. 29), the legal representative and the importer entity belong to the legal-document items; design, materials, intended use, sterilization method, software version, the technical content of labeling and instructions for use, and storage conditions belong to the technical-document items. The value of this method is that it is verifiable — any dispute can be resolved by returning to the statutory lists rather than by appealing to personal experience.

2. The fee gap is surface cost; time is the real expense

The difference between COP 826,546 and COP 1,060,243 is not large for a single product. But a misclassification leads to rejection and re-filing: the 90-day deficiency response period is consumed, a single missed response is treated as a suspension, and during that period the product cannot be lawfully marketed under the new status. For an order waiting on a completed change before it can ship, the time lost dwarfs the fee gap. This inverted cost structure is exactly why GRZAN assigns the classification decision to its regulatory team and keeps a documented record whenever it accepts a change mandate.

3. Multiple changes must be separated, and some changes are actually new registrations

When the same product involves both a titular change and an adjustment of technical parameters, the two channels differ in review path and document list, and a combined filing is often split at the intake stage. GRZAN recommends filing separately and sequencing them deliberately: if the titular change affects the signing entity of subsequent technical documents, file the legal-nature change first and the technical-nature change second. Going further, when the substance of a change is the creation of a different product — for example, an intended-use extension into an entirely new clinical application, or a design change that moves the risk classification up — it has left the change channel altogether and should be re-filed as a new registration application under Art. 16 / Art. 17.

4. Practical recommendations

  1. Regulatory affairs leads: build a change classification worksheet, tagging each item as belonging to Art. 18 or Art. 19, and obtain regulatory team confirmation before filing.
  2. Chinese manufacturers: add a review node asking whether a Colombia registration change is triggered into the change-control process for design changes, material substitutions and revisions of instructions for use.
  3. Registration holder (titular): handle changes to the titular name or address first, because they affect the signing entity of every subsequent filing.
  4. Regulatory affairs leads: schedule multiple changes with the legal nature first and the technical nature after; do not file them combined.
  5. Importers: when the importer entity changes, check in parallel whether the CCAA still covers the changed scope of business (valid 5 years; re-inspection must be requested at least 5 business days in advance).
  6. Finance and commercial teams: budget at the current rates, distinguishing the COP 826,546 and COP 1,060,243 categories.

5. Verification checklist

  • □ Every change item has been listed and tagged with its place in Art. 18 or Art. 19
  • □ The classification of each change (legal nature / technical nature) has been re-checked and documented by the regulatory team
  • □ The filing order for multiple changes has been set (legal nature first, technical nature after)
  • □ The POA (Art. 29) has been confirmed valid on the filing date and throughout the review period
  • □ It has been assessed whether the change constitutes a new product, switching to the new-registration path if necessary
  • □ The budget has been reserved at the current rates (COP 826,546 or COP 1,060,243)

Regulatory information verified as of October 29, 2026

All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.

— GRZAN Regulatory Team

GRZAN provides post-market compliance support for the Colombian market, including registration changes and renewals, technovigilance and adverse event reporting, recall and field corrective action execution, and inspection readiness before INVIMA. If you need a second opinion on how to classify a planned change, or end-to-end handling of your change filings, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail